|
|
|
|
|
|
|
09.11.26 - 22:54
|
Novanta Announces Financial Results for the Third Quarter 2026 (Business Wire)
|
|
|
Third Quarter 2026 GAAP Revenue increased 23% to $305 million
Third Quarter 2026 GAAP Net Income was $2 million, and Adjusted EBITDA increased 38% to $80 million
Third Quarter 2026 GAAP Diluted EPS was $0.05, and Adjusted Diluted EPS increased 21% to $1.05
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2026.
Financial Highlights
Three Months Ended
(In millions, except per share amounts)
October 2,
September 26,
2026
2025
GAAP
Revenue
$
305.0
$
247.8
Operating Income
$
13.9
$
21.8
Net Income
$
2.0
$
10.7
Diluted EPS
$
0.05
$
0.30
Non-GAAP*
Adjusted Operating Income
$
65.1
$
47.4
Adjusted Diluted EPS
$
1.05
$
0.87
Adjusted EBITDA
$
80.3
$
58.1
*Reconciliations of GAAP to non-GAAP financial measures, as well ...
|
|
|
|
|
13.10.26 - 23:03
|
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2026 results after the close of U.S. financial markets on Monday, November 9, 2026.
The Company will host a conference call on Tuesday, November 10, 2026 at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. The replay will remain available until Monday, December 28, 2026.
About Novanta
Novanta is a leading global supplier of core technology solution...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.08.26 - 22:48
|
Novanta Announces Financial Results for the Second Quarter 2026 (Business Wire)
|
|
|
Second Quarter 2026 GAAP Revenue increased 10% to $266 million
Second Quarter 2026 GAAP Net Income was $13 million, and Adjusted EBITDA increased 16% to $61 million
Second Quarter 2026 GAAP Diluted EPS was $0.30, and Adjusted Diluted EPS increased 17% to $0.89
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2026.
Financial Highlights
Three Months Ended
(In millions, except per share amounts)
July 3,
June 27,
2026
2025
GAAP
Revenue
$
265.8
$
241.0
Operating Income
$
18.1
$
14.9
Net Income
$
12.5
$
4.5
Diluted EPS
$
0.30
$
0.12
Non-GAAP*
Adjusted Operating Income
$
47.5
$
40.7
Adjusted Diluted EPS
$
0.89
$
0.76
Adjusted EBITDA
$
60.7
$
52.2
*Reconciliations of GAAP to non-GAAP financial measures, as well as ...
|
|
|
|
|
27.07.26 - 14:06
|
Novanta Completes Acquisition of Riverpoint Medical (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today announced that it has completed the acquisition of Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”) from Arlington Capital Partners. Riverpoint is a category leader in high-growth minimally invasive surgical consumables, including advanced surgical fibers and related technologies for sports medicine, trauma and cardiovascular surgical applications.
“Riverpoint Medical is a market-leading, high-growth surgical consumables business growing revenue and cash flow at twice Novanta's rate, and the acquisition is expected to double Novanta's recurring medical consumables revenue to roughly $300 million while pushing medical end-market exposure to 60% of total revenue,” said Matthijs Glastra, Novanta's Chair & Chief Executive Officer. “Beyond the top-line boost, we believe the deal unlocks a $2 billion in...
|
|
|
15.07.26 - 16:31
|
Novanta Aktie: Mit Übernahme das Wachstum weiter ankurbeln (Aktiencheck)
|
|
|
Paris (www.aktiencheck.de) - Novanta-Aktienanalyse von BNP Paribas:
Egmond Haidt von BNP Paribas nimmt die Aktie des US-Anbieters von Präzisionskomponenten für Medizintechnik- und Industrieunternehmen Novanta Inc. (ISIN: CA67000B1040, WKN: A2AJW7, Ticker-Symbol: 1GSN, NASDAQ-Symbol: NOVT) unter die Lupe. [mehr]...
|
|
|
14.07.26 - 23:03
|
Novanta Inc. Announces Schedule of Second Quarter 2026 Earnings Release and Conference Call (Business Wire)
|
|
|
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 results after the close of U.S. financial markets on Wednesday, August 5, 2026.
The Company will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com.
A replay of the audio webcast will be available approximately three hours after the conclusion of the call on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. The replay will remain available until Monday, October 5, 2026.
About Novanta
Novanta is a leading global supplier of core technology solutions...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
